Approaches for estimating minimal clinically important differences in systemic lupus erythematosus

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
osteoarthritis 1 rheumatologydiseases
rheumatoid arthritis 2 rheumatologydiseases
rituximab 1 rheumatologydiseasesdrugs
systemic lupus erythematosus 3 rheumatologydiseases
arthritis 3 rheumatologydiseases
autoimmune disease 1 rheumatologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
rituximab 6955 the abatacept [[15]] trials - have all reported non-statistically significant results. In the case of rituximab , this is especially disappointing in light of several smaller uncontrolled trials that suggested potential
Select Disease Character Offset Disease Term Instance
arthritis 10755 developed a core set of outcome domains for rheumatic diseases (as had originally been done for rheumatoid arthritis clinical trials) [[25], [26]]. Specifically, they have recommended that the following constitute a core
arthritis 19757 provide an example from a study of a comprehensive rehabilitation intervention among patients with osteo arthritis by using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and the SF-36 to estimate
arthritis 25026 SLE, a study determining the MCID in activity limitation, fatigue, and sleep quality among rheumatoid arthritis patients initially used an internal-anchor approach, and after the preliminary MCID values were determined,
autoimmune disease 3308 patients, clinicians, or policy-makers.Systemic lupus erythematosus (SLE) is a chronic, multi-system autoimmune disease that illustrates some of the challenges posed by defining and measuring MCIDs. SLE is a heterogeneous
osteoarthritis 19752 provide an example from a study of a comprehensive rehabilitation intervention among patients with osteoarthritis by using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and the SF-36 to estimate
rheumatoid arthritis 10744 have developed a core set of outcome domains for rheumatic diseases (as had originally been done for rheumatoid arthritis clinical trials) [[25], [26]]. Specifically, they have recommended that the following constitute a core
rheumatoid arthritis 25015 context of SLE, a study determining the MCID in activity limitation, fatigue, and sleep quality among rheumatoid arthritis patients initially used an internal-anchor approach, and after the preliminary MCID values were determined,
systemic lupus erythematosus 105 Title: Arthritis Research & TherapyApproaches for estimating minimal clinically important differences in systemic lupus erythematosus Sharan K RaiJinoos YazdanyPaul R FortinJ Antonio AviƱa-ZubietaPublication date (epub): 6/2015Publication
systemic lupus erythematosus 605 concept in 1989, studies focused primarily on statistical significance. As most recent clinical trials in systemic lupus erythematosus (SLE) have failed to show significant effects, determining a clinically relevant threshold for outcome
systemic lupus erythematosus 5277 treatment recommendations for patients [[2], [8]].Minimal clinically important difference in the context of systemic lupus erythematosus The Belimumab in Subjects With Systemic Lupus Erythematosus (BLISS)-52 [[9]] and BLISS-76 [[10]] trials

You must be authorized to submit a review.